Akorn, Inc. has added two injectable drug products to its API Supply and Margin Sharing Agreement with Natco Pharma Ltd. One of the ANDA drug products is for the prevention of nausea and vomiting associated with cancer chemotherapy, and the other product is for the reduction of renal toxicity and xerostomia in cancer patients undergoing chemotherapy and radiation. According to 2006 IMS data, the market size for the two finished products is approximately $433 million. Under the agreement, N...